Ishihara M, Kubota T, Watanabe M, Kawano Y, Narai S, Yasui N, Otani Y, Teramoto T, Kitajima M
Department of Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan.
Oncol Rep. 1999 May-Jun;6(3):621-5. doi: 10.3892/or.6.3.621.
A combined antitumor activity of mitomycin C (MMC) and interferon gamma-1a (IFN-gamma) was evaluated to be synergistic by the 3-(4, 5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide assay and human tumor xenografts/severe combined immunodeficient (SCID) mouse system using colon cancer cell lines. The experimental metastasis of WiDr cells in SCID mouse was inhibited by MMC and IFN-gamma with their synergism. Intracellular uptake of MMC in WiDr cells in vitro was significantly increased by IFN-gamma, suggesting the mode of synergism of these agents. This model may also partly explain the antitumor activity of combined MMC, 5-fluorouracil and interleukin-2 treatment on hepatic metastasis of colon cancer.
通过3-(4,5-二甲基噻唑-2)-2,5-二苯基-2H溴化四氮唑试验以及使用结肠癌细胞系的人肿瘤异种移植/严重联合免疫缺陷(SCID)小鼠系统,评估了丝裂霉素C(MMC)和干扰素γ-1a(IFN-γ)的联合抗肿瘤活性,结果显示二者具有协同作用。MMC和IFN-γ协同抑制了WiDr细胞在SCID小鼠中的实验性转移。体外实验中,IFN-γ显著增加了WiDr细胞对MMC的细胞内摄取,提示了这两种药物的协同作用模式。该模型也可能部分解释了MMC、5-氟尿嘧啶和白细胞介素-2联合治疗对结肠癌肝转移的抗肿瘤活性。